Dartmouth Health Continuing Education for Professionals Home, AXL - Advanced Opioid Use Disorder X-waiver Team Learning Collaborative: Opioid Use Disorders Co-morbid with Alcohol, Sedative, Stimulant, or Tobacco Use Disorders: A Person Centered Approach, 9/1/2021 8:00:00 AM - 9/1/2024 9:00:00 AM, This series is designed to increase treatment capacity for opioid use disorders by training more prescribers to be able to treat substance or opioid use disorders.
Content includes:
• Benzodiazepines and OUD
• Tobacco and Vaping
• Alcohol and OUD
• Stimulants and OUD
Presenters
• Geoffrey P. Kane, MD, MPH, is Chief of Addiction Services at the Brattleboro Retreat. He is certified by the American Board of Internal Medicine and the American Board of Addiction Medicine and is a Fellow of the American Society of Addiction Medicine. Since 1988, Dr. Kane has served as medical director of addiction services in both psychiatric and general hospitals. He is Editor and has been the principal contributor to Addiction Medicine Updates on the website of the National Council on Alcoholism and Drug Dependence.
• Sarah Cosgrove, RCP, C-TTSM, AE-C, is a Respiratory Therapist, Master Certified Tobacco Treatment Specialist and a Certified Asthma Educator providing tobacco cessation services at Rutland Regional Medical Center and consulting services for the Vermont Department of Health and Vermont Blueprint for Health. She provides training and mentoring of Tobacco Treatment Specialists across Vermont and serves as an Asthma Educator in the home setting and clinic and provides community education and presentations pertaining to asthma and tobacco and is a spokesperson for 802Quits. She also prepares health care professionals as Asthma Educators (ALA Asthma Institute) and consultant for Tobacco Free Campus and Smoke free housing.
• Suzan R. White, DO, is the Medical Director of Addiction Psychiatry for Phoenix House New England in Vermont. Dr. White is Board Certified in Psychiatry and Addiction. She is passionate about leading others in the direction of their optimal health and realizes this journey is different for everyone. Since graduating with academic honors from the University of New England College of Osteopathic Medicine in 2010, she has been devoted to working in the field of addiction. As an osteopathic physician she is committed to treating patients in a holistic manner that takes into consideration the state of each individual’s mind, body and spirit.
• Kevin Buchanan, MD, PhD, is the Medical Director at the Clara Martin Center providing leadership, vision and oversight of all medical services for the acute and long-term behavioral health services agency. He also provides direct clinical care through the Community Support, Adult Outpatient, and Substance Abuse programs. Dr. Buchanan received his PhD in Neuroanatomy and MD from Loma Linda University. He has been certified by the American Board of Psychiatry/Neurology since 2002.
Learning Outcome(s)
At the conclusion of this learning collaborative, (at least 75% of) participants will be able to identify at least three evidence-based strategies that are designed to enhance the clinical team-based care of patients with substance or opioid use disorders treatment.
Disclosure
The activity director(s), planning committee member(s), speaker(s), author(s) or anyone in a position to control the content for this activity have reported NO financial relationship(s)* with ineligible companies**.
* A “financial relationship" includes employee, researcher (named as the PI), consultant, advisor, speaker, independent contractor (including contracted research), royalties or patent beneficiary, executive role, and/or an ownership interest (not including stocks owned in a managed portfolio).
** An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
Bibliographic Resources
• Miller W, and Sanchez, VC.,. Motivating young adults for treatment and lifestyle change. In: Howard G, ed. Issues in Alcohol Use and Misuse in Young Adults. Notre Dame, IN: University of Notre Dame Press; 1993:55-82.
• US Food and Drug Administration. FDA urges caution about withholding opioid addiction medications from patients taking benzodiazepines or CNS depressants: careful medication management can reduce risks. 2017; https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-urges-caution-about-withholding-opioid-addiction-medications. Accessed June 2, 2021.
• Deaths Involving Psychostimulants Increasing Steadily Since 2014. CDC WONDER Online Database; 2020. https://www.cdc.gov/nchs/products/databriefs/db356.htm. Accessed June 2, 2021.
• O’Donnell J, Matt Gladden, M., Mattson, CL., Hunter, CT., Davis, NL.,. Vital Signs: Characteristics of Drug Overdose Deaths Involving Opioids and Stimulants — 24 States and the District of Columbia, January–June 2019. Morbidity and Mortality Weekly Report (MMWR) 2020; September 4, 2020 / 69(35);1189–1197:https://www.cdc.gov/mmwr/volumes/69/wr/mm6935a1.htm?s_cid=mm6935a1_w. Accessed June 2, 2021.
• Substance Abuse and Mental Health Services Administration. Results From The 2015 National Survey On Drug Use And Health: Detailed Tables In: and CfBHS, Quality, eds2015.
• Pacific Institute for Research and Evaluation. A Closer Look at Stimulant Use: Findings from the Vermont Opioid Use Harm Reduction Evaluation. 2020.
• van Emmerik-van Oortmerssen K, van de Glind G, van den Brink W, et al. Prevalence of attention-deficit hyperactivity disorder in substance use disorder patients: A meta-analysis and meta-regression analysis. Drug and Alcohol Dependence. 2012;122(1):11-19.
• van de Glind G, van den Brink W, Koeter MWJ, et al. Validity of the Adult ADHD Self-Report Scale (ASRS) as a screener for adult ADHD in treatment seeking substance use disorder patients. Drug and Alcohol Dependence. 2013;132(3):587-596.
• Schubiner H, Tzelepis, A., Milberger, S., Lickhart, N., Kruger, M., Kelley, BJ., Schoener, EP., . Prevalence of Attention-Deficit/Hyperactivity Disorder and Conduct Disorder Among Substance Abusers. Journal of Clinical Psychiatry 2000;61:244-251.
• Levin FR, Evans SM, Kleber HD. Prevalence of adult attention-deficit hyperactivity disorder among cocaine abusers seeking treatment. Drug and Alcohol Dependence. 1998;52(1):15-25.
• Wilens TE. Attention-deficit/hyperactivity disorder and the substance use disorders: the nature of the relationship, subtypes at risk, and treatment issues. Psychiatr Clin North Am. 2004;27(2):283-301.
• Wilens TE, Biederman J, Mick E. Does ADHD affect the course of substance abuse? Findings from a sample of adults with and without ADHD. Am J Addict. 1998;7(2):156-163.
• Crunelle CL, van den Brink W, Moggi F, et al. International Consensus Statement on Screening, Diagnosis and Treatment of Substance Use Disorder Patients with Comorbid Attention Deficit/Hyperactivity Disorder. European Addiction Research. 2018;24(1):43-51.
• Levin FR, Mariani JJ, Specker S, et al. Extended-Release Mixed Amphetamine Salts vs Placebo for Comorbid Adult Attention-Deficit/Hyperactivity Disorder and Cocaine Use Disorder: A Randomized Clinical Trial. JAMA Psychiatry. 2015;72(6):593-602.
• Trivedi MH, Walker R, Ling W, et al. Bupropion and Naltrexone in Methamphetamine Use Disorder. N Engl J Med. 2021;384(2):140-153.
• Rawson RA, Chudzynski J, Mooney L, et al. Impact of an exercise intervention on methamphetamine use outcomes post-residential treatment care. Drug Alcohol Depend. 2015;156:21-28.
• Trivedi MH, Greer TL, Rethorst CD, et al. Randomized Controlled Trial Comparing Exercise to Health Education for Stimulant Use Disorder: Results From the CTN-0037 Stimulant Reduction Intervention Using Dosed Exercise (STRIDE) Study. J Clin Psychiatry. 2017;78(8):1075-1082.
• A Clinical Practice Guideline for Treating Tobacco Use and Dependence: 2008 Update: A U.S. Public Health Service Report. American Journal of Preventive Medicine. 2008;35(2):158-176.
Content includes:
• Benzodiazepines and OUD
• Tobacco and Vaping
• Alcohol and OUD
• Stimulants and OUD
Presenters
• Geoffrey P. Kane, MD, MPH, is Chief of Addiction Services at the Brattleboro Retreat. He is certified by the American Board of Internal Medicine and the American Board of Addiction Medicine and is a Fellow of the American Society of Addiction Medicine. Since 1988, Dr. Kane has served as medical director of addiction services in both psychiatric and general hospitals. He is Editor and has been the principal contributor to Addiction Medicine Updates on the website of the National Council on Alcoholism and Drug Dependence.
• Sarah Cosgrove, RCP, C-TTSM, AE-C, is a Respiratory Therapist, Master Certified Tobacco Treatment Specialist and a Certified Asthma Educator providing tobacco cessation services at Rutland Regional Medical Center and consulting services for the Vermont Department of Health and Vermont Blueprint for Health. She provides training and mentoring of Tobacco Treatment Specialists across Vermont and serves as an Asthma Educator in the home setting and clinic and provides community education and presentations pertaining to asthma and tobacco and is a spokesperson for 802Quits. She also prepares health care professionals as Asthma Educators (ALA Asthma Institute) and consultant for Tobacco Free Campus and Smoke free housing.
• Suzan R. White, DO, is the Medical Director of Addiction Psychiatry for Phoenix House New England in Vermont. Dr. White is Board Certified in Psychiatry and Addiction. She is passionate about leading others in the direction of their optimal health and realizes this journey is different for everyone. Since graduating with academic honors from the University of New England College of Osteopathic Medicine in 2010, she has been devoted to working in the field of addiction. As an osteopathic physician she is committed to treating patients in a holistic manner that takes into consideration the state of each individual’s mind, body and spirit.
• Kevin Buchanan, MD, PhD, is the Medical Director at the Clara Martin Center providing leadership, vision and oversight of all medical services for the acute and long-term behavioral health services agency. He also provides direct clinical care through the Community Support, Adult Outpatient, and Substance Abuse programs. Dr. Buchanan received his PhD in Neuroanatomy and MD from Loma Linda University. He has been certified by the American Board of Psychiatry/Neurology since 2002.
Learning Outcome(s)
At the conclusion of this learning collaborative, (at least 75% of) participants will be able to identify at least three evidence-based strategies that are designed to enhance the clinical team-based care of patients with substance or opioid use disorders treatment.
Disclosure
The activity director(s), planning committee member(s), speaker(s), author(s) or anyone in a position to control the content for this activity have reported NO financial relationship(s)* with ineligible companies**.
* A “financial relationship" includes employee, researcher (named as the PI), consultant, advisor, speaker, independent contractor (including contracted research), royalties or patent beneficiary, executive role, and/or an ownership interest (not including stocks owned in a managed portfolio).
** An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
Bibliographic Resources
• Miller W, and Sanchez, VC.,. Motivating young adults for treatment and lifestyle change. In: Howard G, ed. Issues in Alcohol Use and Misuse in Young Adults. Notre Dame, IN: University of Notre Dame Press; 1993:55-82.
• US Food and Drug Administration. FDA urges caution about withholding opioid addiction medications from patients taking benzodiazepines or CNS depressants: careful medication management can reduce risks. 2017; https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-urges-caution-about-withholding-opioid-addiction-medications. Accessed June 2, 2021.
• Deaths Involving Psychostimulants Increasing Steadily Since 2014. CDC WONDER Online Database; 2020. https://www.cdc.gov/nchs/products/databriefs/db356.htm. Accessed June 2, 2021.
• O’Donnell J, Matt Gladden, M., Mattson, CL., Hunter, CT., Davis, NL.,. Vital Signs: Characteristics of Drug Overdose Deaths Involving Opioids and Stimulants — 24 States and the District of Columbia, January–June 2019. Morbidity and Mortality Weekly Report (MMWR) 2020; September 4, 2020 / 69(35);1189–1197:https://www.cdc.gov/mmwr/volumes/69/wr/mm6935a1.htm?s_cid=mm6935a1_w. Accessed June 2, 2021.
• Substance Abuse and Mental Health Services Administration. Results From The 2015 National Survey On Drug Use And Health: Detailed Tables In: and CfBHS, Quality, eds2015.
• Pacific Institute for Research and Evaluation. A Closer Look at Stimulant Use: Findings from the Vermont Opioid Use Harm Reduction Evaluation. 2020.
• van Emmerik-van Oortmerssen K, van de Glind G, van den Brink W, et al. Prevalence of attention-deficit hyperactivity disorder in substance use disorder patients: A meta-analysis and meta-regression analysis. Drug and Alcohol Dependence. 2012;122(1):11-19.
• van de Glind G, van den Brink W, Koeter MWJ, et al. Validity of the Adult ADHD Self-Report Scale (ASRS) as a screener for adult ADHD in treatment seeking substance use disorder patients. Drug and Alcohol Dependence. 2013;132(3):587-596.
• Schubiner H, Tzelepis, A., Milberger, S., Lickhart, N., Kruger, M., Kelley, BJ., Schoener, EP., . Prevalence of Attention-Deficit/Hyperactivity Disorder and Conduct Disorder Among Substance Abusers. Journal of Clinical Psychiatry 2000;61:244-251.
• Levin FR, Evans SM, Kleber HD. Prevalence of adult attention-deficit hyperactivity disorder among cocaine abusers seeking treatment. Drug and Alcohol Dependence. 1998;52(1):15-25.
• Wilens TE. Attention-deficit/hyperactivity disorder and the substance use disorders: the nature of the relationship, subtypes at risk, and treatment issues. Psychiatr Clin North Am. 2004;27(2):283-301.
• Wilens TE, Biederman J, Mick E. Does ADHD affect the course of substance abuse? Findings from a sample of adults with and without ADHD. Am J Addict. 1998;7(2):156-163.
• Crunelle CL, van den Brink W, Moggi F, et al. International Consensus Statement on Screening, Diagnosis and Treatment of Substance Use Disorder Patients with Comorbid Attention Deficit/Hyperactivity Disorder. European Addiction Research. 2018;24(1):43-51.
• Levin FR, Mariani JJ, Specker S, et al. Extended-Release Mixed Amphetamine Salts vs Placebo for Comorbid Adult Attention-Deficit/Hyperactivity Disorder and Cocaine Use Disorder: A Randomized Clinical Trial. JAMA Psychiatry. 2015;72(6):593-602.
• Trivedi MH, Walker R, Ling W, et al. Bupropion and Naltrexone in Methamphetamine Use Disorder. N Engl J Med. 2021;384(2):140-153.
• Rawson RA, Chudzynski J, Mooney L, et al. Impact of an exercise intervention on methamphetamine use outcomes post-residential treatment care. Drug Alcohol Depend. 2015;156:21-28.
• Trivedi MH, Greer TL, Rethorst CD, et al. Randomized Controlled Trial Comparing Exercise to Health Education for Stimulant Use Disorder: Results From the CTN-0037 Stimulant Reduction Intervention Using Dosed Exercise (STRIDE) Study. J Clin Psychiatry. 2017;78(8):1075-1082.
• A Clinical Practice Guideline for Treating Tobacco Use and Dependence: 2008 Update: A U.S. Public Health Service Report. American Journal of Preventive Medicine. 2008;35(2):158-176.
